Pulmonary Pharmacology & Therapeutics

Papers
(The median citation count of Pulmonary Pharmacology & Therapeutics is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Celebrating the appointment of Mario Cazzola as Honorary Editor of Pulmonary Pharmacology & Therapeutics94
Shedding light on vitamin D in tuberculosis: A comprehensive review of clinical trials and discrepancies37
Improvement of asthma control in adult patients using extrafine inhaled beclomethasone/formoterol fixed combination as maintenance therapy as well as maintenance and reliever therapy – CONTROL study30
Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)28
Evaluation of body weight–based dosing, alternative dosing regimens, and treatment interruptions for α1-proteinase inhibitors and implications on biochemical efficacy in patients with α1-antitrypsin d27
Cefepime pharmacokinetics in adult extracorporeal membrane oxygenation patients25
Pharmacokinetic variability of CFTR modulators from standard and alternative regimens20
Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation20
S1PR1 attenuates pulmonary fibrosis by inhibiting EndMT and improving endothelial barrier function18
Editorial Board17
Relative bioavailability of budesonide/glycopyrrolate/formoterol fumarate triple therapy delivered using next generation propellants with low global warming potential16
Editorial Board16
Exploring the role of β2- and β3-adrenergic receptors in cystic fibrosis14
Chronic obstructive pulmonary disease and emerging ER stress-related therapeutic targets14
FTO regulates the proliferation and apoptosis of pulmonary artery smooth muscle cells through m6A demethylation modification13
The tolerability and efficacy of antifibrotic therapy in patients with idiopathic pulmonary fibrosis: Results from a real-world study13
Establishment of multicenter COVID-19 therapeutics preclinical test system in Republic of Korea12
Anlotinib prove to be a potential therapy for the treatment of pulmonary fibrosis complicated with lung adenocarcinoma12
Real-life impact of genotype and severity of lung disease on efficacy of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis12
Comparing the outcomes of intrapleural fibrinolytic and DNase therapy versus intrapleural fibrinolytic or DNase therapy: A systematic review and meta-analysis12
Effects of corticosteroids on Covid-19 patients: A systematic review and meta-analysis on clinical outcomes12
Ferroptosis mediates airway epithelial E-cadherin dysfunction in LPS-induced acute lung injury11
Unveiling the protective role of sevoflurane in video-assisted thoracoscopic surgery associated-acute lung injury: Inhibition of ferroptosis11
Triple inhaled therapy in asthma: Beliefs, behaviours and doubts11
Evaluating the pharmacokinetics of beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide delivered via pressurised metered-dose inhaler using a low global warming potential propellant11
Impact on beclometasone dipropionate pharmacokinetics when switching to a low global warming potential propellant in a pressurised metered-dose inhaler11
Efficacy and safety of sequential combination therapy for pulmonary arterial hypertension: A meta-analysis of Randomized-Controlled Trials11
The era of multiple biologics: Is combination and switching an option in the management of severe asthma?10
Editorial Board10
Patients with moderate to severe COVID-19 outcomes on remdesivir according to baseline 4C mortality score10
The incidence and prognosis of other iatrogenic immunodeficiency-associated lymphoproliferative disorders of the lung related to methotrexate: A retrospective study9
Editorial Board9
Ensifentrine approval: A milestone in the treatment of COPD9
Nebulized amphotericin B for preventing exacerbations in allergic bronchopulmonary aspergillosis: A systematic review and meta-analysis9
Editorial Board9
Editorial Board9
Bispecific domain antibody attenuates airway hyperresponsiveness and pulmonary inflammation in ovalbumin-lipopolysaccharide induced asthma model by inhibiting IL-23 and TNF-α8
Remote preconditioning combined with nebulized budesonide alleviate lipopolysaccharide induced acute lung injury via regulating HO-1 and NF-κB in rats8
Protective effects of adipose-derived biogenic nanoparticles on the pulmonary microvascular endothelial barrier in mice with ventilator-induced lung injury via the TRPV4/ROCK1 signalling pathway8
Scoping review: The state of research on cryptogenic organizing pneumonia therapeutics8
Strongyloides venezuelensis-derived venestatin ameliorates asthma pathogenesis by suppressing receptor for advanced glycation end-products-mediated signaling8
Suboptimal peak inspiratory flow rate in dry-powder inhaler users for chronic obstructive pulmonary disease in Korea8
Corrigendum to “Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/indacaterol/glycopyrronium in patients 8
The wonders of stem cells therapeutic application towards chronic obstructive pulmonary disease8
β-sitosterol targets glucocorticoid receptor to reduce airway inflammation and remodeling in allergic asthma7
The efficacy and safety of inhaled antibiotics for pneumonia: A systematic review and meta-analysis7
Chronic inhaled antibiotic therapy in people with cystic fibrosis with Pseudomonas aeruginosa infection in Germany7
Inhaled nebulised unfractionated heparin (UFH) for the treatment of hospitalised patients with COVID-19: A randomised controlled pilot study7
Repeated doses of captopril induce airway hyperresponsiveness by modulating the TRPV1 receptor in rats7
Considerations into pharmacogenomics of COVID-19 pharmacotherapy: Hope, hype and reality7
Reduction in asthma exacerbation rate after mepolizumab treatment initiation in patients with severe asthma: A real-world database study in Japan7
Inflammatory and contractile profile in LPS-challenged equine isolated bronchi: Evidence for IL-6 as a potential target against AHR in equine asthma7
Safety and tolerability of inhaled antibiotics in patients with bronchiectasis6
Editorial Board6
ALDH2 attenuates radiation-induced lung injury by inhibiting ROS and epithelial-mesenchymal transition mediated by the TGF-β1/Smad pathway6
Effect of daily dosing with tiotropium against methacholine induced bronchoconstriction in asthmatics6
Tyvaso DPI: Drug-device characteristics and patient clinical considerations6
Treatment of respiratory viral infections through inhalation therapeutics: Challenges and opportunities6
Inhaled delivery of a lipid nanoparticle encapsulated messenger RNA encoding a ciliary protein for the treatment of primary ciliary dyskinesia6
Association between pre-ICU aspirin administration and ARDS mortality in the MIMIC-IV database: A cohort study6
Efficacy and safety of house dust mite subcutaneous immunotherapy in polysensitized children with allergic asthma6
Activating transcription factor 6 in the endothelial context6
The immunomodulatory effects of macrolide antibiotics in respiratory disease6
Editorial Board5
Serum exosomal m6A demethylase FTO promotes gefitinib resistance in non-small cell lung cancer by up-regulating FLRT3, PTGIS and SIRPα expression5
Targeted inhibition of IDO1 by Kushenol A enhances radiosensitivity in non-small cell lung cancer5
Experimental modeling of pulmonary fibrosis and combined emphysema in mice using repeated doses of bleomycin and cigarette smoke extract5
Icaritin protects against airway inflammation by inhibiting the TLR4/NF-κB pathway in vivo and in vitro5
SIRT3 alleviates sepsis-induced acute lung injury by inhibiting pyroptosis via regulating the deacetylation of FoxO3a5
Medication use in people with cystic fibrosis before and after modulator therapy5
Serum dipeptidyl peptidase-4 and eosinophil cationic protein levels in patients of bronchial asthma5
Tolerability and efficacy of second-line antifibrotics in patients with idiopathic pulmonary fibrosis5
Which LABA/LAMA should be chosen in COPD patients in real life?5
Pulmonary drug delivery for acute respiratory distress syndrome5
Corrigendum to “Bleomycin induced lung fibrosis increases work of breathing in the mouse” [Pulm. Pharmacol.Therapeut. 25 (2012) 281-285]5
Preventive effect of LCZ696 on hypoxic pulmonary hypertension in rats via regulating the PI3K/AKT signaling pathway5
HDAC8-inhibitor PCI-34051-induced exosomes inhibit human bronchial smooth muscle cell proliferation via miR-381-3p mediated TGFB35
Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate4
Effects of elexacaftor-tezacaftor-ivacaftor on daily treatment burden and airflow obstruction in adults with cystic fibrosis4
The impact of nintedanib and pirfenidone on lung function and survival in patients with idiopathic pulmonary fibrosis in real-life setting4
Nontuberculous mycobacterial (NTM) infections in bronchiectasis patients: A retrospective US registry cohort study4
Comparative biochemical efficacy analysis of an alpha1-proteinase inhibitor (Glassia®) in patients with alpha-1 antitrypsin deficiency4
Demethyleneberberine alleviates Pseudomonas aeruginosa-induced acute pneumonia by inhibiting the AIM2 inflammasome and oxidative stress4
Hyperbaric oxygen therapy as an immunomodulatory intervention in COVID-19-induced ARDS: Exploring clinical outcomes and transcriptomic signatures in a randomised controlled trial4
Dexmedetomidine reduces IL-4 and IgE expression through downregulation of theTLR4/NF-κB signaling pathway to alleviate airway hyperresponsiveness in OVA mice4
Effect of roflumilast on airway remodeling in asthmatic mice exposed to or not exposed to cigarette smoke: Comparison with the effect of dexamethasone4
Are short courses of antibiotic therapy as effective as standard courses for COPD exacerbations? A systematic review and meta-analysis4
Clinical efficacy of inhaled corticosteroids in equine asthma: A meta-analysis and number needed to treat4
Impact of statin treatment and exposure on the risk of chronic allograft dysfunction in Chinese lung transplant recipients3
Effect of centrally and peripherally acting GABAB agonism on the healthy human cough reflex3
Statins’ still controversial role in pulmonary fibrosis: What does the evidence show?3
Impact of beta blockers on resting respiratory rate in older adults: A cross-sectional study3
An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta Syndrome3
Transcriptional factor MAZ promotes cisplatin-induced DNA damage repair in lung adenocarcinoma by regulating NEIL33
The low global warming potential propellant HFA-152a does not induce bronchoconstriction or impair mucociliary clearance3
Efficacy and safety of selexipag, an oral prostacyclin receptor agonist for the treatment of pulmonary hypertension: A meta-analysis3
IRE1α/XBP-1 promotes β-catenin signaling activation of airway epithelium in lipopolysaccharide-induced acute lung injury3
Preliminary study regarding the predicted body weight-based dexamethasone therapy in patients with COVID-19 pneumonia3
Corrigendum to “Presence and function of β-adrenergic receptors in primary equine bronchial epithelia cells” [Pulm Pharmacol Ther. (2020 Apr) 61 101897] DOI: 10.1016/j.pupt.2020.1018973
Sildenafil for idiopathic pulmonary fibrosis: A systematic review and meta-analysis3
Up-regulation of PPAR-γ involved in the therapeutic effect of icariin on cigarette smoke-induced inflammation3
Inhaled vs. intravenous vasodilators in perioperative pulmonary hypertension during chest surgery using cardiopulmonary bypass: A systematic review and meta-analysis3
The effect of bradykinin 1 receptor antagonist BI 1026706 on pulmonary inflammation after segmental lipopolysaccharide challenge in healthy smokers3
A retro-inverso modified peptide alleviated ovalbumin-induced asthma model by affecting glycerophospholipid and purine metabolism of immune cells3
The compound artemisinin-hydroxychloroquine ameliorates bleomycin-induced pulmonary fibrosis in rats by inhibiting TGF-β1/Smad2/3 signaling pathway3
0.44970297813416